Policy & Regulation
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/...
GSK seeks European approval for single-dose Bexsero booster in older children and adults
20 July 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) reported on Monday that the European Medicines Agency has accepted its submission to update the Bexsero label to include a singl...
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
20 July 2026 - Evaxion A/S, a Denmark-based, clinical-stage TechBio company developing novel vaccines with its AI-Immunology platform, said on Friday that it will present three-year clinical efficacy ...
Ananda Pharma doses first patient in MRX1 clinical trial of patients with chemotherapy induced peripheral neuropathy
20 July 2026 - UK biopharmaceutical company Ananda Pharma Limited announced on Friday that the first patient taking part in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's ...
Aqemia and Sanofi expand drug discovery collaboration with new research target
17 July 2026 - Generative AI drug development company Aqemia announced on Friday an expansion of its multi-year drug discovery collaboration with French healthcare company Sanofi S.A. (Euronext Paris:...
Camurus' FDA accepts CAM2029 NDA resubmission for acromegaly, sets December decision date
17 July 2026 - Swedish biopharmaceutical company Camurus AB (STO:CAMX) said on Friday that the US Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application for CA...